Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA,…
ReNAgade Therapeutics, the company unlocking the limitless potential of RNA medicines, appoints Paul Perrault to its board of directors, effective December 5, 2023. I announced what I had done. Mr. Perrault most…
Merck, a leading science and technology company, today announced that its two Phase III EVOLUTION clinical trials (evolutionRMS 1 and evolutionRMS 2) investigating the efficacy and safety of evobrutinib did…
Registration as an organ and tissue donor is a crucial component to Donor Alliance’s mission of saving and healing lives in the region. In Colorado, nearly all organ and tissue donor…
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced the appointment of Paul Perreault to its Board of Directors, effective December 5, 2023. Mr. Perreault most recently…
CG Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track Designation and Breakthrough Therapy Designation for cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive…
STEMCELL Technologies, Canada’s largest biotechnology company, has received the Canada’s Most Admired Corporate Cultures™ of 2023 award by Waterstone Human Capital. This national awards program recognizes best-in-class Canadian organizations for fostering…
Hologic, Inc. (Nasdaq: HOLX) will showcase several recent developments in next-generation AI solutions at the 109th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov.…
Natura Bissé and Arch Amenities Group Europe today announce a collaboration agreement with the aim of increasing their presence in the luxury spa sector throughout the European Union and the…
The University of Wisconsin School of Medicine and Public Health at UW–Madison and GE HealthCare announced today a 10-year strategic collaboration that builds on an iconic relationship spanning more than…
Cofactor Genomics, the company bridging the precision medicine gap, today announced successful validation of the OncoPrism immunotherapy predictive diagnostic assay, enabling physicians to use the test to help guide treatment…
BioMimetix JV, LLC, a clinical-stage biotechnology company developing metalloporphyrins, a novel drug class for the treatment of cancer patients, today announced the presentation of encouraging data from its Phase 2…